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BACKGROUND
There are a variety of growth hormone delivery devices (GHDD) available to children requiring 
growth hormone (GH) therapy. Many paediatric endocrine nurses can o er patients and their 
families a choice of the products that are available, which can sometimes be overwhelming. 
However, factors such a licensed clinical indications have to be considered, as well as cost. 
Patient choice for growth hormone devices is well documented in the literature, with regards 
to compliance (Ahmed et al. 2008, Gau & Takasawa 2017, Kapoor et al. 2008, van Dongen & 
Kaptein 2012, Wickramasuriya et al. 2006), with onus on the parents and children making the 
 nal choice for the delivery of growth hormone.
However, research has shown (Ayyar & George 2016) that involving the health care 
professional (HCP) within the decision making process can have an in uence on the desired 
GHDD, although the HCP referred to was the prescribing Doctor . The 
proposed model (Elwyn et al. 2012) is seen below.
AIMS
The purpose of this project was to explore whether other factors suggested by paediatric 
endocrine nurses should be considered when exploring choice of GHDD, within the shared 
decision making model.
RESULTS
Nurses had a variety of devices to choose from (N=11): three groups had chosen di erent 
devices (N=3) apart from two groups had chosen the same device. In uencing themes that 
emerged included: knowledge of patients learning di  culties, social and housing implications, 
child’s body composition, child friendly device design, and ease of use. Cost was also 
discussed, but was not the deciding factor for a  nal decision. 
METHODS
Participating nurses (N=10) attended an interactive and detailed training session on all of 
the GHDD currently available within the UK. Subsequently, each nurse was given a box 
of marketing materials for each GHDD, including training materials, patient information 
literature and DVDs. The nurses were given  ve case study scenarios on di erent conditions. 
The scenarios re ected the  ve licensed indications for GH in children in the UK. The patients 
were  ctional but were representative of the typical complex patient that paediatric 
endocrine nurses see within the clinic environment. Nurses were advised to work in pairs. In 
their pairs, the nurses were asked to feed back =on their choice of GHDD, detailing why they 
had chosen that speci c device, utilising a problem based learning approach. Themes were 
extrapolated using thematic analysis. 
CASE STUDY SCENARIOS
TURNERS SYNDROME
Jade is 7 and lives at home with both parents. Mum has 
learning di  culties and Dad is partially sighted. They are 
known to social services and receive support. Jade is on the 
autistic spectrum and has challenging behaviour. She has 
recently been diagnosed with Turner syndrome. She is to 
start GH at a dose of 1.5mg daily.
PRADER WILLI SYNDROME
Bonnie is 3 years old and lives at home 
with her Mother, two older siblings and 
two dogs. Bonnie stays overnight with her 
Dad for one night every other weekend. 
Bonnie has been diagnosed with PWS 
and has been advised to start GH. She 
weighs 20kg. She has only recently begun 
walking and prefers to ‘bottom shu  e’. 
GROWTH HORMONE DEFICIENCY
Joseph is 6 and the second of four children (youngest sibling is 
3 months old). He lives with both parents but Dad works long 
hours and is often not around at bedtime. Joseph is adamant 
he will not have injections. His Mum is struggling with the new 
baby and doesn’t have any support from Dad with regards to 
GH treatment as Dad is on the 2nd centile for adult Male height 
and doesn’t see being small as an issue. The Consultant at the 
local hospital wants him to start on 0.5mg daily.
SMALL FOR GESTATIONAL AGE
Arthur is 4 and starting school soon. 
He has always been small and had failure 
to thrive in his  rst year – he remains a 
picky eater. Mum and Dad are concerned 
that he looks about 2 and worried he will 
be picked on at school. They both work full 
time and have a lot of support from both 
sets of Grandparents – Arthur frequently 
goes to stay with his grandparents if 
Mum and Dad are travelling with work. 
Arthur has recently had his pre-school 
vaccinations and reacted very badly 
to having the injections. Mum is very 
concerned about how Arthur is going 
to manage having GH every day. He is 
to start on 0.3mg daily.
SHOX DEFICIENCY
Neelam is 14 and has recently been diagnosed with SHOX 
de ciency. She lives with her parents and two younger 
brothers in a two bedroom  at. Neelam speaks good English 
and has to translate for her parents at hospital appointments. 
Neelam is very small for her age – only 138cm and keen to 
start treatment. She is 38kg.
RESULTS – THEMES
Theme Influencing factors Aspect of GH device
Parent
- Learning disability
- Partially sighted
- Language barrier
- Audible sounds
- No reconstitution
- Simple cartridge replacement
- Pre set dose
- Adherence monitoring
- Translated instructions
Child
- Fear of needles
- Learning disability
- Body composition:
- SGA ↓ body fat
- PWS ↑ body fat
- Ease of use
- Needle length
- Smaller needle
- Hidden needle
Social and housing
- Parents work full time
- Grandparents main carers
-  Living in di erent home
/split family
- No need to refrigerate
- Ease of use
- No reconstitution
- Pre set dose
SHARED DECISION MAKING MODEL
1 – Choice talk
Parents and children 
are shown GH devices 
with no Dr input
2 – Option talk
Discussion is held 
regarding knowledge, 
looking at options, pros 
and cons, and exploring 
why they have chosen 
their preferred device, 
with the Dr explaining 
reasons for di erent 
options3 – Decision talk
Move to a decision 
with further information 
on the device
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CONCLUSIONS
Themes that emerged from the study demonstrate that the nurses’ clinical judgement and 
prior knowledge of the patient’s needs is an intrinsic factor to consider when implementing 
patient choice in GHDD.
CLINICAL IMPLICATIONS
Further research needs to be conducted on a larger scale to examine nurses’ thoughts and 
opinions on the di erent GHDDs available, and the need to remain conscious of underlying 
issues which may not be obvious or apparent to the child and family. From this, a reduced 
number of choice of devices can therefore be demonstrated to children and their families, 
thereby giving the nurse more time to focus on the most appropriate devices. Implementation 
of the shared decision making model utilizing paediatric endocrine nurses, and not necessarily 
the prescribing doctor, is suggested to be used within the GHDD choice process.
GROWTH HORMONE DELIVERY DEVICES
THANKS
to the students on the 2017 intake 
of the CPPD module ‘Principles of 
care for children and young people 
in endocrinology’
FOR FURTHER 
INFORMATION
kate.davies@lsbu.ac.uk
NURSES’ VIEWPOINTS ON GROWTH HORMONE DELIVERY DEVICES
Davies, K and Bryan, S
Department of Children’s Nursing
London South Bank University, London, UK
